

Accepted Manuscript

Title: The antifungal arsenal: alternative drugs and future targets

Author: Nathan P. Wiederhold

PII: S0924-8579(17)30334-5

DOI: <http://dx.doi.org/doi: 10.1016/j.ijantimicag.2017.09.002>

Reference: ANTAGE 5259

To appear in: *International Journal of Antimicrobial Agents*



Please cite this article as: Nathan P. Wiederhold, The antifungal arsenal: alternative drugs and future targets, *International Journal of Antimicrobial Agents* (2017), <http://dx.doi.org/doi: 10.1016/j.ijantimicag.2017.09.002>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The Antifungal Arsenal: Alternative Drugs and Future Targets

Nathan P. Wiederhold

Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science

Center at San Antonio, San Antonio, TX, USA

Corresponding Author:

Nathan P. Wiederhold, PharmD

UTHSCSA

Pathology

7703 Floyd Curl Drive

San Antonio, TX 78229

wiederholdn@uthscsa.edu

Highlights

- VT-1161, VT-1129, and VT-1598 have greater specificity for fungal Cyp51 than mammalian CYP 450 enzymes
- CD101 and SCY-078 target 1,3- β -D-glucan and may offer advantages over available echinocandins
- VT-1598, CD101, and SCY-078 have *in vitro* activity against the emerging pathogen *Candida auris*
- AX001 targets GPI biosynthesis and has potent, broad-spectrum antifungal activity
- F901318 targets fungal pyrimidine biosynthesis with potent activity against certain moulds

Download English Version:

<https://daneshyari.com/en/article/8738608>

Download Persian Version:

<https://daneshyari.com/article/8738608>

[Daneshyari.com](https://daneshyari.com)